Antonio Jose Naranjo-Redondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Antonio Jose Naranjo-Redondo has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Nagaraju Bandaru
Department of Pharmacology, School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra, India
4 shared publications - Perli Kranti Kumar
School of Pharmaceutical Sciences, Sandip University, Nashik, Maharashtra, 422213
4 shared publications - Sandesh Lodha
Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India
4 shared publications - Shrikant Shivkumar Nilewar
Department of Pharmaceutical Chemistry, Maliba Pharmacy College, Uka Tarsadia University, Bardoli 394350, Gujarat, India
4 shared publications - Tushar Janardan Pawar
Centro de Investigación, Universidad Anáhuac Querétaro, Circuito Universidades I, Fracción 2 S/N, Zibatá, El Marqués 76246, Querétaro, Mexico
4 shared publications - Ankita R. Pradhan
School of Pharmaceutical Science, Sandip University, Nashik 422213, Maharashtra, India
2 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 842
Exploiting the T790M Gatekeeper: A Theoretical Blueprint for Non-Covalent Inhibition of in cis Triple-Mutant EGFR
Background/Objectives: The EGFR T790M mutation drives lung cancer resistance by sterically hindering inhibitors and restoring ATP affinity. As C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur as a primary stabilizing anchor rather than a liability. Methods: A generative AI framework (DrugEx) sampled 100,000 molecules, prioritized via QSAR classification (ROC-AUC: 0.91 ± 0.01) and Applicability Domain (AD) mapping. The workflow was de-risked through retrospective benchmarking against the DUD-E database (35,590 molecules), achieving a 1% Enrichment Factor of 5.19. Lead candidates underwent 100 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability was quantified via Free Energy Landscape (FEL) analysis and ensemble-averaged MM-GBSA binding free energy calculations. Results: Candidate 106 demonstrated exceptional mutation tolerance by redistributing interactions toward the Met790 sulfur atom. MD analysis confirmed potency is dictated by successful recruitment of the thioether environment, locking the complex within a narrow thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol) corroborated by an equipotent MM-GBSA ΔGbind of −50.51 kcal/mol in the mutant system, driven by persistent π-sulfur contacts (85% occupancy). Conclusions: These results indicates that potential T790M resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This modeled mutation-aware framework provides a candidate non-covalent strategy to be validated in future wet-lab campaigns.
- 10 July 2026
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (7) , 842
Open AccessExploiting the T790M Gatekeeper: A Theoretical Blueprint for Non-Covalent Inhibition of in cis Triple-Mutant EGFR
Background/Objectives: The EGFR T790M mutation drives lung cancer resistance by sterically hindering inhibitors and restoring ATP affinity. As C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur as a primary stabilizing anchor rather than a liability. Methods: A generative AI framework (DrugEx) sampled 100,000 molecules, prioritized via QSAR classification (ROC-AUC: 0.91 ± 0.01) and Applicability Domain (AD) mapping. The workflow was de-risked through retrospective benchmarking against the DUD-E database (35,590 molecules), achieving a 1% Enrichment Factor of 5.19. Lead candidates underwent 100 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability was quantified via Free Energy Landscape (FEL) analysis and ensemble-averaged MM-GBSA binding free energy calculations. Results: Candidate 106 demonstrated exceptional mutation tolerance by redistributing interactions toward the Met790 sulfur atom. MD analysis confirmed potency is dictated by successful recruitment of the thioether environment, locking the complex within a narrow thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol) corroborated by an equipotent MM-GBSA ΔGbind of −50.51 kcal/mol in the mutant system, driven by persistent π-sulfur contacts (85% occupancy). Conclusions: These results indicates that potential T790M resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This modeled mutation-aware framework provides a candidate non-covalent strategy to be validated in future wet-lab campaigns.
- Open Access
- 29 April 2026
- Published by MDPI AG in Preprints.org
Exploiting the T790M Mutation: Sulfur-Anchoring as a New Paradigm for Non-Covalent EGFR Inhibition
Background/Objectives: The EGFR T790M gatekeeper mutation drives resistance in non-small cell lung cancer by sterically hindering inhibitors and restoring ATP affinity. As emerging C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur atom as a primary stabilizing anchor rather than a liability. Methods: A reinforcement learning-based generative AI framework (DrugEx) sampled 100,000 molecules, prioritized through QSAR-based classification (mean ROC-AUC: 0.91 ± 0.01) and physicochemical filtering. Four lead candidates underwent 200 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability and energetic convergence were quantified via Free Energy Landscape (FEL) analysis, post-simulation Ramachandran validation, and ensemble-averaged Molecular Mechanics Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Results: Candidate 106 demonstrated high mutation tolerance by redistributing interactions toward the Met790 sulfur atom, contrasting with reference scaffolds 14 and 88 which suffered significant affinity loss. MD analysis revealed that potency is fundamentally dictated by successful recruitment of the thioether environment, locking the complex within a narrow, well-defined thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol by docking) corroborated by a robust MM-GBSA ΔGbind of −50.51 kcal/mol, primarily driven by persistent π-sulfur contacts (85% occupancy). Ramachandran analysis confirmed over 90% favored region occupancy, ensuring interactions occur without non-physical protein strain. Conclusions: Successful T790M/C797S resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This mutation-aware blueprint provides a non-covalent strategy that avoids the metabolic and resistance-prone liabilities of covalent warheads.
- 29 April 2026
- Published by MDPI AG in Preprints.org
Open AccessExploiting the T790M Mutation: Sulfur-Anchoring as a New Paradigm for Non-Covalent EGFR Inhibition
Background/Objectives: The EGFR T790M gatekeeper mutation drives resistance in non-small cell lung cancer by sterically hindering inhibitors and restoring ATP affinity. As emerging C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur atom as a primary stabilizing anchor rather than a liability. Methods: A reinforcement learning-based generative AI framework (DrugEx) sampled 100,000 molecules, prioritized through QSAR-based classification (mean ROC-AUC: 0.91 ± 0.01) and physicochemical filtering. Four lead candidates underwent 200 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability and energetic convergence were quantified via Free Energy Landscape (FEL) analysis, post-simulation Ramachandran validation, and ensemble-averaged Molecular Mechanics Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Results: Candidate 106 demonstrated high mutation tolerance by redistributing interactions toward the Met790 sulfur atom, contrasting with reference scaffolds 14 and 88 which suffered significant affinity loss. MD analysis revealed that potency is fundamentally dictated by successful recruitment of the thioether environment, locking the complex within a narrow, well-defined thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol by docking) corroborated by a robust MM-GBSA ΔGbind of −50.51 kcal/mol, primarily driven by persistent π-sulfur contacts (85% occupancy). Ramachandran analysis confirmed over 90% favored region occupancy, ensuring interactions occur without non-physical protein strain. Conclusions: Successful T790M/C797S resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This mutation-aware blueprint provides a non-covalent strategy that avoids the metabolic and resistance-prone liabilities of covalent warheads.
- Open Access
- 4 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3286
Dual-Site Acetylcholinesterase Inhibition and Multiscale Stability of Fused Quinoline Sulfonamides: A Chemoinformatic GA-MLR and Molecular Dynamics Study
Alzheimer’s disease (AD) represents an escalating global neuropharmacological crisis, with prevalence in high-growth demographic regions such as India projected to exceed 14 million by 2040. This study addresses the urgent need for high-potency, dual-site acetylcholinesterase (AChE) inhibitors through an integrated computational pipeline. We address the failure of mono-target paradigms by designing scaffolds capable of simultaneously anchoring the Catalytic Active Site (CAS) and the Peripheral Anionic Site (PAS). A robust GA-MLR QSAR model was developed from 115 quinoline analogs using 11,135 descriptors. Lead candidates were prioritized via cavity directed molecular docking (7XN1) and 100 ns molecular dynamics (MD) simulations. The five-descriptor model (R2 = 0.7569, = 0.7244) was validated by an external set of 8 experimental compounds ( = 0.8620). Lead Compound 19 emerged as a superior candidate (ΔG = −11.1 kcal/mol), exhibiting a stable MD trajectory (PL-RMSD ≈ 2.4 Å) and preserving essential Gly121-His447 catalytic anti-correlations. This study provides a statistically validated scaffold and computational mechanistic foundation for future in vitro experimental validation, advancing the high throughput screening of neuroprotective agents on a global scale.- 4 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (7) , 3286
Open AccessDual-Site Acetylcholinesterase Inhibition and Multiscale Stability of Fused Quinoline Sulfonamides: A Chemoinformatic GA-MLR and Molecular Dynamics Study
Alzheimer’s disease (AD) represents an escalating global neuropharmacological crisis, with prevalence in high-growth demographic regions such as India projected to exceed 14 million by 2040. This study addresses the urgent need for high-potency, dual-site acetylcholinesterase (AChE) inhibitors through an integrated computational pipeline. We address the failure of mono-target paradigms by designing scaffolds capable of simultaneously anchoring the Catalytic Active Site (CAS) and the Peripheral Anionic Site (PAS). A robust GA-MLR QSAR model was developed from 115 quinoline analogs using 11,135 descriptors. Lead candidates were prioritized via cavity directed molecular docking (7XN1) and 100 ns molecular dynamics (MD) simulations. The five-descriptor model (R2 = 0.7569, = 0.7244) was validated by an external set of 8 experimental compounds ( = 0.8620). Lead Compound 19 emerged as a superior candidate (ΔG = −11.1 kcal/mol), exhibiting a stable MD trajectory (PL-RMSD ≈ 2.4 Å) and preserving essential Gly121-His447 catalytic anti-correlations. This study provides a statistically validated scaffold and computational mechanistic foundation for future in vitro experimental validation, advancing the high throughput screening of neuroprotective agents on a global scale. - Open Access
- 12 March 2026
- Published by MDPI AG in Preprints.org
Dual-Site Acetylcholinesterase Inhibition and Multiscale Stability of Fused Quinoline Sulfonamides: A Chemoinformatic GA-MLR and Molecular Dynamics Study
Alzheimer’s disease (AD) represents a escalating global neuropharmacological crisis, with prevalence in high-growth demographic regions such as India projected to exceed 14 million by 2040. This study addresses the urgent need for high-potency, dual-site acetylcholinesterase (AChE) inhibitors through an integrated computational pipeline. Background: We address the failure of mono-target paradigms by designing scaffolds capable of simultaneously anchoring the Catalytic Active Site (CAS) and the Peripheral Anionic Site (PAS). Methods: A robust GA-MLR QSAR model was developed from 115 quinoline analogues using 11,135 descriptors. Lead candidates were prioritized via blind molecular docking (7XN1) and 100-ns molecular dynamics (MD) simulations. Results: The five-descriptor model (R2 = 0.7569, QLOO2 = 0.7244) was validated by an external set of 8 experimental compounds (Rext2 = 0.8620). Lead Compound 19 emerged as a superior candidate (ΔG = -11.1 kcal/mol), exhibiting a stable MD trajectory (PL-RMSD ≈ 2.4 Å) and preserving essential Gly121-His447 catalytic anti-correlations. Conclusions: This study provides a statistically validated scaffold and mechanistic foundation for future biomimetic chromatography validation, advancing the high-throughput screening of neuroprotective agents on a global scale.
- 12 March 2026
- Published by MDPI AG in Preprints.org
Open AccessDual-Site Acetylcholinesterase Inhibition and Multiscale Stability of Fused Quinoline Sulfonamides: A Chemoinformatic GA-MLR and Molecular Dynamics Study
Alzheimer’s disease (AD) represents a escalating global neuropharmacological crisis, with prevalence in high-growth demographic regions such as India projected to exceed 14 million by 2040. This study addresses the urgent need for high-potency, dual-site acetylcholinesterase (AChE) inhibitors through an integrated computational pipeline. Background: We address the failure of mono-target paradigms by designing scaffolds capable of simultaneously anchoring the Catalytic Active Site (CAS) and the Peripheral Anionic Site (PAS). Methods: A robust GA-MLR QSAR model was developed from 115 quinoline analogues using 11,135 descriptors. Lead candidates were prioritized via blind molecular docking (7XN1) and 100-ns molecular dynamics (MD) simulations. Results: The five-descriptor model (R2 = 0.7569, QLOO2 = 0.7244) was validated by an external set of 8 experimental compounds (Rext2 = 0.8620). Lead Compound 19 emerged as a superior candidate (ΔG = -11.1 kcal/mol), exhibiting a stable MD trajectory (PL-RMSD ≈ 2.4 Å) and preserving essential Gly121-His447 catalytic anti-correlations. Conclusions: This study provides a statistically validated scaffold and mechanistic foundation for future biomimetic chromatography validation, advancing the high-throughput screening of neuroprotective agents on a global scale.